Since CD72 is a negative regulator of the B-cell receptor (BCR) signaling pathway, activation of the BCR signaling pathway by specific drugs can promote CD72 expression in B-ALL cells through a negative feedback mechanism, thereby providing additional targets for CD72-directed CAR-T therapy [42]. Here, BCR is linked to acute lymphoblastic leukemia.